SYRE.US Spyre Therapeutics Inc.

Healthcare Biotechnology USA Stocks
93.81 USD
Close of Nov 18, 2026
23.01 110.64
Market cap
USD 8.91B
P/E
-
P/B
10.42x
ROE
-25.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SYRE.US undervalued?

Graham number

The Graham number of Spyre Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spyre Therapeutics Inc. fundamental analysis

No fundamental analysis for Spyre Therapeutics Inc. yet.

Spyre Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spyre Therapeutics Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to…

Full company profile